Bionano Genomics, Inc. (BNGO) Stock Score, Valuation & Financial Research
Bionano Genomics, Inc. is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 21/100.
Quick answer for BNGO
Bionano Genomics, Inc. currently has a Wall Street Score of 21/100. The stored market price is $1.33. Its financial score is 22/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Bionano Genomics, Inc. does
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and
BNGO financial snapshot
- Wall Street Score:
- 21/100
- Current price:
- $1.33
- Market capitalization:
- $15.3M
- Revenue:
- $30.2M
- Net income:
- $-32.2M
- Free cash flow:
- $-16.3M
- Cash:
- $3.7M
- Total debt:
- $6.7M
- EPS:
- -3.73
- Financial score:
- 22/100
- Valuation score:
- 0/100
- Revenue score:
- 26/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-16.3M, showing cash burn in the current stored period.
- The balance sheet shows $3.7M of cash versus $6.7M of total debt, so leverage deserves attention.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 22/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BNGO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.